2024 ADC Insights and Trends

Out of the many bioconjugate strategies employed, ADCs have long been the most successful. After a ‘rocky’ patch in the mid-2010s with no new approvals, the ‘second wave’ of ADCs is well and truly on its way.​

This analysis reveals how this ‘second coming’ has benefitted from the difficult lessons learned and harsh realities faced by the ‘pioneering’ ADCs, such as reduced time in clinic and better molecule design to minimize toxicity. And acts as a reminder, of why continual learning is an excellent driver of innovation.

These insights and market knowledge have been developed based on the analysis and fusion of data collated from a variety of sources by the Hanson Wade Intelligence team, elevating the quality of insights compared to Beacon data alone​:

• ​Beacon ADC database: Vast repository of highly granular, current and historical data on ADCs including payloads; exploration by the Hanson Wade Intelligence of its deepest recesses and use of smart interpretation facilitates in-depth understanding of trends and trajectories at quantitative scale, and over long time periods ​

• External sources: Datapoints from additional external sources were used to complement existing Beacon data; clever inference and data fusion was used to increase the relevance and meaning of the outputs, enabling a higher quality of insights​